Rentschler Appoints Mark Caswell as Vice President, US Facility Site Head

Rentschler Biopharma has appointed Mark Caswell as Vice President and Site Head. He joined Rentschler in July 2022 and is managing all operations at the company’s US facilities in Milford, MA.

Caswell has more than 25 years of experience in the biopharmaceutical industry. Prior to joining Rentschler, he worked for over six years at Lonza Biologicals, most recently as Head of Operations at the Portsmouth, NH site. Before that, he worked for many years at Sanofi Genzyme (previously Genzyme) in positions of increasing responsibility.

“I am excited to welcome Mark Caswell to the Rentschler team. His many years of experience in the biopharma and CDMO space and diverse background in various areas of operations make him the perfect leader to run our US operations,” said Frank Mathias, CEO of Rentschler. “An important part of his responsibilities will be overseeing the completion of our state-of-the-art RBMC facility, the largest expansion in Rentschler Biopharma’s 150-year history.”

The responsibilities of Martin Kessler in his role as CEO of Rentschler Biopharma Inc. have been transferred to Caswell.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.